Docetaxel and irinotecan combination chemotherapy in advanced esophageal cancer

Satish P Shanbhag, Barbara Burtness

Research output: Contribution to journalArticle

Abstract

Metastatic esophageal cancer is incurable with 5-year survival rates of under 5% using currently available therapeutic strategies. Palliative chemotherapy with cisplatin- and 5-fluorouracil (5FU)-based regimens remains the standard of care for patients with recurrent unresectable or metastatic esophageal cancer. Upfront cisplatin-based regimens are poorly tolerated in some patient groups and, for patients with recurrent disease after platinum-based therapies, there is a need for an alternate efficacious regimen without significant toxicities. The combination of docetaxel and irinotecan is an active regimen in this disease and has been investigated in several phase II trials. Weekly dosing of chemotherapy is preferred over a once every 3 weeks regimen on account of comparable efficacy and improved toxicity profile. Future directions include investigation of pharmacogenomic treatment assignment, particularly as irinotecan appears to be active in tumors with high ERCC1 expression, which tend to be resistant to cisplatin. Combinations with biologics such as bevacizumab and cetuximab, which have shown additive benefit with other cytotoxic combinations, are also of interest for future study.

Original languageEnglish (US)
JournalEuropean journal of Clinical and Medical Oncology
Volume3
Issue number1
StatePublished - 2011
Externally publishedYes

Fingerprint

irinotecan
docetaxel
Esophageal Neoplasms
Combination Drug Therapy
Cisplatin
Drug Therapy
Pharmacogenetics
Standard of Care
Platinum
Biological Products
Fluorouracil
Therapeutics
Survival Rate
Neoplasms

Keywords

  • Docetaxel
  • ERCC1
  • Esophageal cancer
  • Irinotecan

ASJC Scopus subject areas

  • Oncology

Cite this

Docetaxel and irinotecan combination chemotherapy in advanced esophageal cancer. / Shanbhag, Satish P; Burtness, Barbara.

In: European journal of Clinical and Medical Oncology, Vol. 3, No. 1, 2011.

Research output: Contribution to journalArticle

@article{59e7cfc29237408f9213b89f5575fa94,
title = "Docetaxel and irinotecan combination chemotherapy in advanced esophageal cancer",
abstract = "Metastatic esophageal cancer is incurable with 5-year survival rates of under 5{\%} using currently available therapeutic strategies. Palliative chemotherapy with cisplatin- and 5-fluorouracil (5FU)-based regimens remains the standard of care for patients with recurrent unresectable or metastatic esophageal cancer. Upfront cisplatin-based regimens are poorly tolerated in some patient groups and, for patients with recurrent disease after platinum-based therapies, there is a need for an alternate efficacious regimen without significant toxicities. The combination of docetaxel and irinotecan is an active regimen in this disease and has been investigated in several phase II trials. Weekly dosing of chemotherapy is preferred over a once every 3 weeks regimen on account of comparable efficacy and improved toxicity profile. Future directions include investigation of pharmacogenomic treatment assignment, particularly as irinotecan appears to be active in tumors with high ERCC1 expression, which tend to be resistant to cisplatin. Combinations with biologics such as bevacizumab and cetuximab, which have shown additive benefit with other cytotoxic combinations, are also of interest for future study.",
keywords = "Docetaxel, ERCC1, Esophageal cancer, Irinotecan",
author = "Shanbhag, {Satish P} and Barbara Burtness",
year = "2011",
language = "English (US)",
volume = "3",
journal = "European journal of Clinical and Medical Oncology",
issn = "1759-8958",
publisher = "San Lucas Medical",
number = "1",

}

TY - JOUR

T1 - Docetaxel and irinotecan combination chemotherapy in advanced esophageal cancer

AU - Shanbhag, Satish P

AU - Burtness, Barbara

PY - 2011

Y1 - 2011

N2 - Metastatic esophageal cancer is incurable with 5-year survival rates of under 5% using currently available therapeutic strategies. Palliative chemotherapy with cisplatin- and 5-fluorouracil (5FU)-based regimens remains the standard of care for patients with recurrent unresectable or metastatic esophageal cancer. Upfront cisplatin-based regimens are poorly tolerated in some patient groups and, for patients with recurrent disease after platinum-based therapies, there is a need for an alternate efficacious regimen without significant toxicities. The combination of docetaxel and irinotecan is an active regimen in this disease and has been investigated in several phase II trials. Weekly dosing of chemotherapy is preferred over a once every 3 weeks regimen on account of comparable efficacy and improved toxicity profile. Future directions include investigation of pharmacogenomic treatment assignment, particularly as irinotecan appears to be active in tumors with high ERCC1 expression, which tend to be resistant to cisplatin. Combinations with biologics such as bevacizumab and cetuximab, which have shown additive benefit with other cytotoxic combinations, are also of interest for future study.

AB - Metastatic esophageal cancer is incurable with 5-year survival rates of under 5% using currently available therapeutic strategies. Palliative chemotherapy with cisplatin- and 5-fluorouracil (5FU)-based regimens remains the standard of care for patients with recurrent unresectable or metastatic esophageal cancer. Upfront cisplatin-based regimens are poorly tolerated in some patient groups and, for patients with recurrent disease after platinum-based therapies, there is a need for an alternate efficacious regimen without significant toxicities. The combination of docetaxel and irinotecan is an active regimen in this disease and has been investigated in several phase II trials. Weekly dosing of chemotherapy is preferred over a once every 3 weeks regimen on account of comparable efficacy and improved toxicity profile. Future directions include investigation of pharmacogenomic treatment assignment, particularly as irinotecan appears to be active in tumors with high ERCC1 expression, which tend to be resistant to cisplatin. Combinations with biologics such as bevacizumab and cetuximab, which have shown additive benefit with other cytotoxic combinations, are also of interest for future study.

KW - Docetaxel

KW - ERCC1

KW - Esophageal cancer

KW - Irinotecan

UR - http://www.scopus.com/inward/record.url?scp=79956081316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956081316&partnerID=8YFLogxK

M3 - Article

VL - 3

JO - European journal of Clinical and Medical Oncology

JF - European journal of Clinical and Medical Oncology

SN - 1759-8958

IS - 1

ER -